Momesso D P, Vaisman F, Caminha L S C, Pessoa C H C N, Corbo R, Vaisman M
Endocrinology Service, Universidade Federal do Rio de Janeiro, Rua Eduardo Guinle 20/904, Rio de Janeiro, 22260-090, Brazil,
J Endocrinol Invest. 2014 Jan;37(1):57-64. doi: 10.1007/s40618-013-0015-z. Epub 2014 Jan 8.
Management of small well-differentiated thyroid cancer (DTC) has generated much debate regarding the surgical approach and radioactive iodine treatment (RAI).
The aim of the study was to evaluate the impact of surgical extension and RAI on the outcome of DTC ≤2 cm.
A retrospective analysis of 176 cases of DTC ≤2 cm was performed.
At diagnosis, tumor size was 1.38 ± 0.55 cm, age 40.2 ± 13.6 years. After a mean follow-up period of 14.1 ± 4.5 years, 15.9 % patients had recurrent/persistent structural disease, with cervical neck disease (thyroid gland area and/or cervical lymph nodes) in 11.9 % cases and distant metastasis in 5.1 %. Disease specific mortality was of 1.1 %. No difference in outcome was observed between patients submitted to total or subtotal thyroidectomy. After total and subtotal thyroidectomy, the rate of recurrent/persistent structural disease was 19.1 and 10.6 % (p = 1.00), respectively. Using the multivariate cox proportion hazards analysis, no difference in the clinical outcome was observed after total or subtotal thyroidectomy (p = 0.703) neither after RAI (p = 0.807). Similar results were observed after stratification by tumor size. Multifocal disease (p = 0.007), extra-thyroid extension (p = 0.007) and presence of lymph node metastasis (p = 0.000) were associated with unfavorable outcome.
Total thyroidectomy and RAI did not improve clinical outcomes of DTC ≤2.0 cm when compared with less extensive surgery and no RAI in selected patients. Therefore, in carefully selected patients with DTC ≤2.0 cm and no unfavorable risk factors (multifocal disease, extra-thyroid extension, lymph node and/or distant metastasis), less extensive surgery and no RAI may be acceptable treatment options.
对于微小分化型甲状腺癌(DTC)的治疗,在手术方式和放射性碘治疗(RAI)方面存在诸多争议。
本研究旨在评估手术范围扩大和RAI对直径≤2 cm的DTC患者预后的影响。
对176例直径≤2 cm的DTC患者进行回顾性分析。
诊断时,肿瘤大小为1.38±0.55 cm,年龄为40.2±13.6岁。平均随访14.1±4.5年后,15.9%的患者出现复发/持续性结构性疾病,其中11.9%为颈部疾病(甲状腺区域和/或颈部淋巴结),5.1%为远处转移。疾病特异性死亡率为1.1%。接受全甲状腺切除术或次全甲状腺切除术的患者在预后方面未观察到差异。全甲状腺切除术和次全甲状腺切除术后,复发/持续性结构性疾病的发生率分别为19.1%和10.6%(p = 1.00)。使用多变量Cox比例风险分析,全甲状腺切除术或次全甲状腺切除术后(p = 0.703)以及RAI治疗后(p = 0.807)在临床结局上均未观察到差异。按肿瘤大小分层后观察到类似结果。多灶性疾病(p = 0.007)、甲状腺外扩展(p = 0.007)和淋巴结转移的存在(p = 0.000)与不良预后相关。
与在部分患者中采用范围较小的手术且不进行RAI相比,全甲状腺切除术和RAI并未改善直径≤2.0 cm的DTC患者的临床结局。因此,对于精心挑选的直径≤2.0 cm且无不良风险因素(多灶性疾病、甲状腺外扩展、淋巴结和/或远处转移)的DTC患者,范围较小的手术且不进行RAI可能是可接受的治疗选择。